The MeCo Score™ is a clinically validated, first-in-class biomarker test that helps identify patients with early-stage breast cancer who have a high risk of relapse [1][2] and may benefit from FDA-approved antifibrotic therapy [3]*.
*The MeCo Score (TM) is for Investigational Use Only and is not cleared or approved by the Food and Drug Administration.
[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293
[2] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.
[3] Data on file with the Spanish National Cancer Research Center (CNIO) and MeCo Diagnostics Holdings, Inc.
Copyright © 2024 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.